Amaero (3DA) Scheme Meeting 2026 presentation summary
Event summary combining transcript, slides, and related documents.
Scheme Meeting 2026 presentation summary
5 Jun, 2026Meeting overview and structure
Three key meetings were held virtually on 5 June 2026: Share Scheme Meeting, Option Scheme Meeting, and Extraordinary General Meeting, each with formal business and voting conducted via the Automic platform.
All meetings were chaired by Hank J. Holland, with the full board and key advisors in attendance.
Shareholders and option holders could submit questions and vote electronically, with detailed instructions provided for participation.
Proxy votes were accepted and counted, with undirected proxies assigned to the Chair and cast in favor of the respective resolutions.
Results of each meeting were to be released on the ASX Announcements Platform and the company website.
Share Scheme Meeting
The Share Scheme Resolution, under section 411 of the Corporations Act, proposed a scheme of arrangement for ordinary shareholders.
Voting results: 99.55% in favor, 0.06% against, 0.40% abstained, indicating overwhelming support.
Shareholders could ask questions and participate in real time during the meeting.
Option Scheme Meeting
The Option Scheme Resolution, also under section 411, proposed a scheme of arrangement for option holders.
Voting results: 96.29% in favor, 0% against, 3.71% abstained, showing strong approval.
Option holders' voting power was determined using the Black-Scholes valuation model.
Latest events from Amaero
- Stockholders voted on equity plans, share issuance, and director compensation changes.3DA
EGM 2026 - Revenue up 376% to $18.1M, but net loss widened; strong backlog amid going concern risk.3DA
H2 2026 - Record revenue growth, strong backlog, and U.S. IPO plans mark a pivotal year.3DA
Q4 2026 TU - Poised for rapid growth, Amaero leads U.S. advanced powder production and targets a U.S. IPO.3DA
IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 - Q3 FY2026 revenue up 301%–347% YoY, FY2026 fully contracted, U.S. redomiciliation advances.3DA
Q3 2026 TU - FY2025 saw record revenue, major supply deals, and facility expansion, setting up strong FY2026 growth.3DA
H2 2025 - Strategic U.S. shift, capital raises, and C103 supply deals set path to EBITDA breakeven by FY2026.3DA
H2 2024 - Revenue up 367%, net loss widens, FY2026 guidance cut amid U.S. contract delays.3DA
H1 2026 - Transition to commercialization, capital raises, and U.S. expansion with new leadership.3DA
AGM 2024